Henlius Seeks To Add RA Indication To Chinese Rituximab

HLX01 Biosimilar Was First Approved In China Under New Pathway

Rheumatoid arthritis
Henlius is seeking to add the rheumatoid arthritis indication to its rituximab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products